key: cord-1040967-hfry2zfy
authors: Robertson, Louise J.; Price, Ruth; Moore, Julie S.; Curry, Grace; Farnan, John; Black, Amy; Blighe, Kevin; Andrew Nesbit, M.; McLaughlin, James A.D.; Moore, Tara
title: IgG antibody production and persistence to 6 months following SARS-CoV-2 vaccination: a Northern Ireland observational study
date: 2022-03-03
journal: Vaccine
DOI: 10.1016/j.vaccine.2022.02.087
sha: 39a3e56badd35d8e1405e18ce41071b4da74a562
doc_id: 1040967
cord_uid: hfry2zfy

BACKGROUND: This study evaluates spike protein IgG antibody response following Oxford-AstraZeneca COVID-19 vaccination using the AbC-19™ lateral flow device. METHODS: Plasma samples were collected from n=111 individuals from Northern Ireland. The majority were >50 years old and/or clinically vulnerable. Samples were taken at five timepoints from pre-vaccination until 6-months post-first dose. RESULTS: 20.3% of participants had detectable IgG responses pre-vaccination, indicating prior COVID-19. Antibodies were detected in 86.9% of participants three weeks after the first vaccine dose, falling to 74.7% immediately prior to the second dose, and rising to 99% three weeks post-second vaccine. At 6-months post-first dose, this decreased to 90.5%. At all timepoints, previously infected participants had significantly higher antibody levels than those not previously infected. CONCLUSION: This study demonstrates that strong anti-spike protein antibody responses are evoked in almost all individuals that receive two doses of Oxford-AstraZeneca vaccine, and largely persist beyond six months after first vaccination.

The global impact of the COVID-19 pandemic resulted in a race to find a safe and effective vaccine. In December 2020, the Pfizer BioNTech (PFZ) vaccine was approved for use in the UK, shortly followed by the ChAdOx1 Oxford-AstraZeneca (OAZ) 1 vaccine. The OAZ vaccine, an adenovirus vector vaccine is a modified, non-replicating, chimpanzee adenovirus which contains DNA coding for SARS-CoV-2 spike protein [1] . The first data on efficacy showed 64% effective after first dose and 70% after second [1] . SARS-CoV-2 neutralising antibodies were reported in 91% of participants following the first dose, and 99-100% following a second dose [2, 3] .

The UK Rapid Test Consortium (UK-RTC) was founded in response to a UK Government call for development of a rapid antibody test for use nationally. The consortium developed the AbC-19™ lateral flow device (LFD) antibody test now approved in Europe and UK for professional use and is available for sale. AbC-19™ is an easy-to-use, accurate and reliable neutralising antibody rapid test indicating positive antibody response post-infection or presence of neutralising antibodies postvaccine [4] . Testing can take place in a wide range of environments and by a range of individuals from varying educational backgrounds as shown in our previously published data [5] .

Antibody testing is vital to inform understanding of the prevalence of SARS-CoV-2 virus in the population. It is important for understanding response to emerging variants, detecting differences in levels of immunity (vaccinated immunity versus infection-acquired immunity) and their durability.

Strategic antibody screening will inform the need for boosters and vaccination strategies globally [6] .

This study assesses SARS-CoV-2 IgG antibody status at five timepoints during vaccination against COVID-19 disease with the OAZ vaccine using the AbC-19™. We also assess natural COVID-19 infection before and during these six months and report the impact of infection pre-and post-vaccination on antibody levels.

The study was an observational study conducted over 5 time-points (up to 6 months post-first dose) on patients scheduled to receive the OAZ COVID-19 vaccine. The study was approved by the South Birmingham Research Ethics Service (REC 20/WM/0184, IRAS 286041) and all participants provided fully informed written consent prior to taking part. All work was carried out in accordance with the Declaration of Helsinki.

Participants were recruited by word-of-mouth or recruitment poster on the day of their first or second vaccination at a GP clinic in Belfast, Northern Ireland. A small number of participants (n=12) were enrolled at the time of their second vaccination, so were only sampled at two timepoints. All participants provided informed consent, basic demographic information and details of any previous positive SARS-CoV-2 test result using REDCap electronic data capture tools hosted at Ulster University (https://www.project-redcap.org/). PANDEMIC study participants that had previously tested positive for COVID-19 were also invited to join the study via email. Participants were eligible for the study if they were over 18 years of age and could attend a blood sample clinic at the time of their first or second vaccination. Exclusion criteria included anyone with a blood disorder or contraindication to giving a blood sample, or anyone currently exhibiting symptoms of COVID-19. Samples were taken at five timepoints: just before first vaccination (TP1), 3 weeks after first vaccination (TP2), just before second vaccination (TP3), 3 weeks after the second vaccination (TP4) and 6 months following first vaccination (TP5), as shown in Supplementary Table 1. An EDTA-plasma (10ml) sample was collected at each time point from each participant. All blood samples were processed within 2 hours of collection in refrigerated centrifuges (15 min, 3000rpm, 4 o C).

Samples were stored at -80 o C until analysis. Analyses were performed on AbC-19™ at Ulster University according to manufacturer's instructions. Assays were performed with samples in batches of 10, with one researcher adding 2.5µL of EDTA-plasma to the assay and a second adding 100µL of buffer immediately following sample addition. After 20 minutes, the strength of resulting test line was scored, independently by three experienced blinded observers, from 0-10 according to a visual score card ( Figure S1 ). In qualitative mode, a score ≥1 is positive. Using the semi-quantitative approach, scores of 1, 2 and 3 are low positive whilst scores of 4, 5, 6, 7, 8, 9 and 10 are high positive.

All data was analysed using Microsoft Excel and GraphPad Prism 9 with figures generated in Prism.

Differences between RT-PCR positive and no RT-PCR results were analysed using two tailed unpaired Welchs t-test and 6 months post vaccine group compared by Brown-Forsythe and Welch one-way ANOVA.

We assessed SARS-CoV-2 IgG antibody status in a total of 111 participants using the AbC-19™ at five timepoints to determine antibody response to OAZ vaccination. AbC-19™ results were graded quantitatively, then classified semi-quantitatively as directed by the manufacturer: test lines were graded as negative, low positive or high positive as described above ( Figure S1 ).

The initial samples were collected at a Belfast GP clinic during March 2021, when access to vaccination was limited to those aged 50 years and above, or those classified as vulnerable or clinically extremely vulnerable. A small number of participants were recruited from previous PANDEMIC study phases who were eligible for vaccination and previously tested positive for COVID-19 [4] . The cohort consisted of 55% female (n=61, aged 28-89 years, median 51 years) and 45% male (n=50, aged 24-82 years, median 51 years) subjects, with an overall age range of 24-89 years (median 51 years old). A total of n=14 participants had tested positive by RT-PCR for SARS-CoV-2 infection before being vaccinated, with a range of 47-219 days (median 104 days) between the positive result and first vaccination.

Samples were collected from n=94 participants at the time of first vaccination (TP1) with n=75 (79.7%) scoring negative by AbC-19™ (n=4 previously infected, Figure 1 ). 14 samples scored low positive 

We have previously shown good laboratory validation performance metrics for AbC-19™ detection of SARS-CoV-2 spike protein IgG antibody in a laboratory-based setting with a sensitivity of 97.58%

(95% CI, 95.28%-98.95%) on a cohort of known positives, and specificity of 99.59% (95% CI, 98.53 %-99.95%) on known negatives, including 223 pre-pandemic samples [4] . We demonstrated excellent overall agreement between antibody levels when measured by three other immunoassays (2021) showed a greater antibody response following PFZ, though a higher OAZ cohort median age may account for the reduced IgG response observed [7] .

Here, we used the AbC-19™ to determine the kinetics of the response to the OAZ vaccination at various timepoints through the vaccination program. 86.9% of participants mounted a detectable IgG antibody response to the first vaccine dose, falling to 74.7% immediately prior to the second dose, and rising to 99% after it, with previously infected participants having a significantly higher quantitative AbC-19™ score than those without at all timepoints. These results are in close agreement with similar studies of antibody response to the OAZ, PFZ and Moderna vaccines measured using a variety of assays -LFD, chemiluminescent immunoassays (CLIA), and chemiluminescent microparticle assays (CMIA) [8] [9] [10] [11] [12] [13] .

In all studies, almost all participants mount a detectable antibody response to two doses of vaccine that is greater in previously infected individuals (either known RT-PCR positive or seropositive at baseline).

Antibody levels have been shown to decline over time following vaccination, but remain detectable for more than 6 months after second vaccination [9, 14, 15] . Titres of neutralizing antibodies have been shown to decay faster in never infected vaccinated individuals than in those infected prior to vaccination [16] . No significant difference in the reduction of AbC-19™ scores between previously infected and never infected individuals was observed in this study (Figure 3 ).

Infection following the second dose of vaccine in previously uninfected individuals results in a high IgG antibody titre with a mean increase in AbC-19™ score of 5.8, significantly higher (p=<0.0001) than the mean decrease in AbC-19™ score of 1.7 observed in doubly vaccinated, uninfected individuals ( Figure   3 ). Similar immune responses to post-vaccination infection were observed in nursing home residents infected following a second dose of PFZ vaccine [17] .

The present study has limitations. Firstly, the largest portion of participants came from the 50+ year old age group being called for vaccination at the time of the study and were representative of the ethnic diversity of the area of Belfast, in which they were recruited (2.2% belonging to minority ethnic groups) [18] . The data that was obtained from younger participants was limited to those individuals called for vaccination due to underlying health problems. Secondly, we assessed antibody levels semiquantitatively with the AbC-19™, a device which we already demonstrated to have a good correlation between other commercially available assays (Roche, Abbott, EuroImmun) [4] . Additionally, a drop in antibody levels in undiluted serum of individuals with high positive (10) scores may not be detected.

Dilution of serum samples by 10-or 100-fold may be necessary [11] . Thirdly, only the humoral (antibody)

immune response was measured in this study; cellular (T cell) responses to vaccination were not investigated. Two vaccine doses have been shown to be required for maximal T cell response, which importantly appear to be directed against SARS-CoV-2 epitopes conserved between the SARS-CoV-2 variant used in the OAZ vaccine and the variants of concern that have subsequently emerged [19] .

In summary, this study demonstrates via AbC-19™ that two doses of the OAZ ChAdOx1 vaccine elicits strong anti-spike protein antibody responses in almost all vaccinated individuals which persist for most individuals beyond six months after first vaccination. The utility of the 20-minute response time AbC-19™ rapid test in confirming this antibody response is also demonstrated. Further follow-up of this cohort at later time points will monitor further decline in antibody levels and help inform the likely need for additional vaccine or booster doses, particularly tailored to emerging strains or for people in whom the greatest decline in antibody levels is seen with time.

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Evaluation of the IgG antibody response to SARS CoV-2 infection and performance of a lateral flow immunoassay: cross-sectional and longitudinal analysis over 11 months

User experience analysis of AbC-19 Rapid Test via lateral flow immunoassays for self-administrated SARS-CoV-2 antibody testing

The Role of Serology Testing to Strengthen Vaccination Initiatives and Policies for COVID-19 in Europe

Cross reactivity of serological response to SARS-CoV-2 vaccination with viral variants of concern detected by lateral flow immunoassays

Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals

Quantitative SARS-CoV-2 antispike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status

Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval homologous dual vaccination in older people

Rapid lateral-flow immunochromatographic tests to assess anti N/S IgG seropositivity after BNT162b2 vaccine: A cross-sectional study: Rapid lateral-flow immunochromatographic tests after BNT162b2 vaccine

Three-month analysis of total humoral response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers

Immunity after COVID-19 and vaccination: follow-up study over 1 year among medical personnel

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose

SARS-CoV-2 infection shortly after BNT162b2 vaccination results in high anti-spike antibody levels in nursing home residents and staff

Census 2011: Key Statistics for Northern Ireland

Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern

The study is sponsored by Abingdon Health, United Kingdom. We thank the phlebotomists and staff at the Group Surgery who made this study possible. Most importantly we are indebted to the participants who donated blood samples during this study.

Professor Tara Moore acted as a consultant for Abingdon Health during the final period of sampling.At time of conception and commencement of this study, none of the authors received payment from Abingdon Health.

The study was funded by Abingdon Health, United Kingdom who also provided the AbC-19™ testing devices. Abingdon Health had no other involvement in the study. All authors attest they meet the ICMJE criteria for authorship.

☐ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☒The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Professor Tara Moore acted as a consultant for Abingdon Health during the final period of sampling. At time of conception and commencement of this study, none of the authors received payment from Abingdon Health.